-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics' TTX-MC138 Meets Primary Safety Endpoint in Phase 1a Trial

PUBT·10/26/2026 11:32:45
Listen to the news
TransCode Therapeutics' TTX-MC138 Meets Primary Safety Endpoint in Phase 1a Trial
  • TransCode Therapeutics presented Phase 1a results for TTX-MC138 in previously treated advanced solid tumors at ESMO Congress 2026 in Madrid.
  • The trial met its primary safety endpoint, with no dose-limiting toxicities observed.
  • Disease stabilization occurred across the heavily pretreated patient population; some patients experienced extended periods without disease progression.
  • TTX-MC138 is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program with Quantum Leap Healthcare Collaborative.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260731PR_NEWS_USPR_____NE80362) on October 26, 2026, and is solely responsible for the information contained therein.